International Clinical Trial: Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer

Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07816666) titled 'Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer' on Sept. 7.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: AstraZeneca

Condition: Platinum-sensitive Relapsed Epithelial Ovarian Cancer Platinum-sensitive Relapsed Fallopian Tube Cancer Platinum-sensitive Relapsed Primary Peritoneal Cancer

Intervention: Drug: Torvutatug samrotecan

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First E...